May 21 (UPI) -- European pharmaceutical company AstraZeneca said Thursday it has received more than $1 billion from the U.S. government to develop its coronavirus vaccine candidate.
The drugmaker has partnered with the University of Oxford on its "AZD1222" vaccine, one of several candidates worldwide in clinical trials.
The funding came from the the Biomedical Advanced Research and Development Authority, a branch of the Department of Health and Human Services.
Image: AstraZeneca plans at least 400 million doses and has lined up manufacturing capacity for one billion doses with first deliveries set for September. File Photo by Drago Prvulovic/EPA